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Abstract
Objective
To determine whether a simple small vessel disease (SVD) score, which uses information
available on rapid visual assessment of clinical MRI scans, predicts risk of cognitive decline and
dementia, above that provided by simple clinical measures.
Methods
Three prospective longitudinal cohort studies (SCANS [StGeorge’s Cognition andNeuroimaging
in Stroke], RUN DMC [Radboud University Nijmegen Diffusion Imaging and Magnetic Reso-
nance Imaging Cohort], and the ASPS [Austrian Stroke Prevention Study]), which covered
a range of SVD severity frommild and asymptomatic to severe and symptomatic, were included. In
all studies, MRI was performed at baseline, cognitive tests repeated during follow-up, and pro-
gression to dementia recorded prospectively. Outcomemeasures were cognitive decline and onset
of dementia during follow-up. We determined whether the SVD score predicted risk of cognitive
decline and future dementia. We also determined whether using the score to select a group of
patients with more severe disease would reduce sample sizes for clinical intervention trials.
Results
In a pooled analysis of all 3 cohorts, the score improved prediction of dementia (area under the
curve [AUC], 0.85; 95% confidence interval [CI], 0.81–0.89) compared with that from clinical
risk factors alone (AUC, 0.76; 95% CI, 0.71–0.81). Predictive performance was higher in
patients with more severe SVD. Power calculations showed selecting patients with a higher
score reduced sample sizes required for hypothetical clinical trials by 40%–66% depending on
the outcome measure used.
Conclusions
A simple SVD score, easily obtainable from clinical MRI scans and therefore applicable in
routine clinical practice, aided prediction of future dementia risk.
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MRI features of cerebral small vessel disease (SVD) are as-
sociated with increased dementia risk,1 but predicting
whether an individual patient with SVD will progress to de-
mentia has not been possible.
One possible approach is to use information available on
clinical MRI scans. An SVD severity score has been pro-
posed2 that is easily applicable in clinic and combines several
MRI markers including lacunar infarcts and white matter
hyperintensities (WMH), as well as cerebral microbleeds
(CMB) and perivascular spaces (PVS), all of which can be
assessed simply and rapidly by visual inspection of clinical
MRI scans. This score has been shown to associate with
cognitive impairment in patients with symptomatic lacunar
stroke and in community populations3,4 but such cross-
sectional studies cannot determine whether it predicts future
risk of dementia and cognitive decline. To address this,
longitudinal studies are required with several years of fol-
low-up.
The aim of this study was to determine whether a simple MRI
score can predict dementia. We examined its performance in 3
prospective longitudinal cohorts, which included patients
with SVD ranging from mild and asymptomatic to severe
and symptomatic. The MRI score2 divides the individual MRI
markers in a binary fashion (i.e., presence or absence).
Therefore we further assessed the effect of including more
detailed information into the scores; for example, by grading
the number of lacunar infarcts and the severity of WMHon an
ordinal scale. We also determined whether using the score to
preselect patients with a higher chance of developing de-
mentia would reduce sample sizes in trials of agents to reduce
cognitive decline in SVD.
Methods
Cohorts studied
Three longitudinal studies were included. St George’s Cog-
nition and Neuroimaging in Stroke (SCANS) included
moderate to severe symptomatic SVD, the Radboud Uni-
versity Nijmegen Diffusion Imaging and Magnetic Resonance
Imaging Cohort (RUN DMC) included all grades of symp-
tomatic SVD, and the Austrian Stroke Prevention Study
(ASPS) covered a community population with mild MRI
evidence of SVD.
Standard protocol approvals, registrations,
and patient consents
Local ethical approval was obtained for each study and each
participant gave written informed consent.
SCANS
Patients with SVDwere screened and invited between 2007 and
2010 from 3 stroke services in South London, United
Kingdom.5,6 SVD was defined as a clinical lacunar stroke syn-
drome as well as confluent WMH on MRI. Participants were
excluded if they presented with any cause of stroke mechanism
other than SVD or a clinical diagnosis of dementia. Study par-
ticipants (n = 121) had multimodal MRI and cognitive tests
performed at baseline and at years 1, 2, and 3 as well as follow-up
for dementia to year 5. Ninety-nine participants returned at 1 or
more time points for MRI measures. For this analysis, we used
MRI data from the baseline visit, cognitive data detecting change
from baseline to year 3, and data collected on progression to
dementia over a 5-year follow-up. MRI sequences performed on
a 1.5T Signa HDxt MRI system (General Electric, Milwaukee,
WI) included whole-brain T1-weighted, fluid-attenuated in-
version recovery (FLAIR), and gradient echo. Follow-up data
on dementia incidence was available for all 121 participants.
RUN DMC
RUN DMC is a prospective study of symptomatic SVD. Full
methodologic details have been published.7 A total of 503
individuals without dementia with radiologic SVD defined as
the presence of 1 or more lacunes or WMH were recruited in
2006. Study participants were assessed at baseline and at
follow-up in 2011 and in 2015. Assessment included cognitive,
MRI, and clinical assessments. We used the baseline MRI data
from the 2006 visit and follow-up data on cognition and in-
cidence of dementia from the 2011 and 2015 visits. Follow-up
data on dementia incidence were available for 501 participants.
MRI sequences, performed on a 1.5T Magnetom scanner
(Siemens, Erlangen, Germany), included whole-brain T1-
weighted, FLAIR, and gradient echo.
ASPS
ASPS is a community-based cohort study in participants
without a history or signs of stroke or dementia inGraz, Austria.
Full methodologic details have been published.8,9 The data
used for our study consisted of 2 cohorts: 871 participants from
the elderly ASPS cohort and 347 from the ASPS-family study.10
A total of 541 participants (194 from ASPS and 347 from the
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family cohort) had completeMRI data available, which allowed
construction of the SVD score, and they were included in the
baseline analysis. A total of 193 of 194 individuals from the
elderly cohort were followed at 3 time points for a maximum of
11 years (median follow-up of 3 years) and data on dementia
incidence were available in all 193. Of the 347 individuals from
the family cohort, 126 were followed at 2 time points for
a maximum of 8 years (median follow-up of 2 years), and
dementia data were available in all 126. There was no difference
between those dropping out of the family cohort in median
(interquartile range [IQR]) age (drop out 68 [55–74] years,
remained in 67 [62–72] years; p = 0.696) or in median (IQR)
years of education (drop out 10 [10–13] years, remained in 10
[10–13] years; p = 0.128), but those dropping out were more
likely to be female (64.2% vs 52.7%; p = 0.035). There was no
overlap between the 2 cohorts and data were combined for
analysis. MRI scans were performed on 1.5T scanners (Gyro-
scan S 15 and ACS; Philips, Eindhoven, the Netherlands) for
elderly cohort participants and included proton density, T2-
weighted sequences, and T1-weighted images. Participants in
the family cohort were examined by a 3T whole body scanner
(TimTrio; Siemens Healthcare, Erlangen, Germany).
Cognition assessments and construction of
cognitive indices
In each cohort, a battery of neuropsychological tests was ad-
ministered and cognitive index scores constructed to allow as-
sessment of global cognition (a measure of overall performance
across all tasks) and 2 specific domains particularly affected in
SVD11: processing speed (PS) and executive function (EF). In-
dex scores for each cognitive domain were calculated by aver-
aging the component global or cognitive measures. The different
tests used to construct the index scores are shown in table 1.
In SCANS,6 the cognitive measures were converted into Z
scores based on published normative data, using age at
baseline for scaling purposes, and then aggregated into the
index scores. For RUN DMC7,12 and ASPS8,9 data, the
measures were converted into Z scores based on the baseline
mean and SDs of the raw scores before aggregation.
Conversion to dementia
In all cohorts, participants developing dementia during follow-
up were identified. In SCANS, dementia was diagnosed using
the DSM-V definition13 of major neurocognitive disorder and
identified as described previously.6 In RUN DMC, dementia
diagnosis was based on DSM-IV criteria as described pre-
viously12; probable Alzheimer disease (AD) was based on
National Institute on Aging–Alzheimer’s Association criteria
and vascular dementia on National Institute of Neurological
Disorders and Stroke–Association Internationale pour la
Recherche en l’Enseignement en Neurosciences criteria.14 In
ASPS, dementia was defined by a Mini-Mental State Exami-
nation score <24 points at follow-up for the majority of par-
ticipants (except 3 participants in whom the diagnosis was
recorded in the medical records), and diagnosis of dementia
subtype (Alzheimer vs vascular) was not available.
Analysis was performed for all-cause dementia and then re-
peated for only vascular dementia cases. For this latter
analysis, only vascular dementia cases were included for
SCANS and RUN DMC but all cases were included from
ASPS.
Generation of total SVD score
A total SVD score was generated as described previously.2
One point was given for the presence of each of any lacunar
infarct, WMH, and CMB. Because PVS data were not
available in RUN DMC, and no correlation had been shown
between PVS counts and cognition previously in SCANS,15
a simple SVD score without PVS was generated, and
therefore the simple SVD score had a range from 0 to 3.
However, to assess the additional predictive value of PVS, an
additional sensitivity analysis was performed to investigate
the impact of excluding PVS information, in which an SVD
score including PVS (0–4) was compared with a simple SVD
score excluding PVS (0–3) in the SCANS and ASPS
datasets.
Table 1 Cognitive tests included in global cognition by
study
Study Cognitive tests included
Global cognition
SCANS Trail-Making Test, Wisconsin Card Sorting Test,
verbal fluency on letters (FAS), BIRT information
processing speed task, Digit Symbol Substitution,
Grooved Pegboard (best-hand), Digit Span Task,
Logical Memory Task, Visual Reproduction Task
RUN DMC Rey Auditory Verbal Learning Test, Rey Complex
Figure Task, Paper-Pencil Memory Scanning Task,
Stroop Test, Symbol Digit Substitution Task, verbal
fluency, Verbal Series Attention Test
ASPS Wiener Reaktionsgera¨t (RT-switched), Purdue
Pegboard Test, Trail-Making Test B, Wisconsin
Card Sorting Test, verbal memory, Figural Memory
(Lern- und Geda¨chtnistest), verbal fluency
Executive function
SCANS Trail-Making Test, Wisconsin Card Sorting Test,
verbal fluency on letters (FAS)
RUN DMC Verbal fluency, Stroop Test, Verbal Series Attention
Test
ASPS Trail-Making Test B, Wisconsin Card Sorting Test
Processing speed
SCANS BIRT information processing speed task, Digit
Symbol Substitution, Grooved Pegboard (best-
hand)
RUN DMC Symbol Digit Substitution Task, Stroop Test, Paper-
Pencil Memory Scanning Task
ASPS Wiener Reaktionsgera¨t (RT-switched),
Purdue Pegboard Test
Abbreviations: ASPS = Austrian Stroke Prevention Study; RUN DMC = Rad-
boud University Nijmegen Diffusion Imaging and Magnetic Resonance Im-
aging Cohort; SCANS = St George’s Cognition and Neuroimaging in Stroke.
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The simple SVD score was alsomodified to determine whether
including more information on the severity of MRI features
affects its performance. In this modified score, WMH were
graded from 0 to 3 using the Fazekas scale,16 and the number of
lacunar infarcts was graded from 0 to 3 (0 = none, 1 = 1 to 2, 2 =
3 to 5, 3 = >5). CMBwere still graded as absent (0) or present.1
The amended SVD score therefore had a range from 0 to 7.
The details of the 2 SVD scores are shown in table 2.
Statistical methods
Analyses were performed for both the simple SVD score and the
amended SVD score. First the association of simple SVD scores
with global cognition, EF, and PS was determined using linear
regression at baseline. Akaike information criterion (AIC) was
estimated to compare the relative fit of statistical models. We
then determined whether the baseline scores (simple and
amended scores) predicted future cognitive decline and pro-
gression to dementia. To determinewhether the scores predicted
dementia, logistic regressionwas performed and the classification
ability of the scores for predicting dementia assessed. The area
under the curve (AUC) was estimated for a model including age,
sex, and education years, and this was compared with a similar
model in which the SVD score was added.
Slopes of change in cognition were estimated using a linear
mixed effect (LME) model utilizing all time points with cog-
nitive information. We then performed analysis of variance to
compare the slopes among simple SVD score groups by using
slopes on an individual level for each study. This was performed
for each study and a p value was presented. All models were
adjusted for age, sex, and years of education.
A sample size calculation was performed for a hypothetical trial
to determine the effect on power of selecting patients with severe
SVD identified by a simple SVD score ≥2. We calculated min-
imum sample sizes per arm with 80% power to detect a range of
treatment effect from 10%, 15%, 20%, 25%, and 30% in the
intervention group. Sample sizes were calculated for 2 outcomes:
(1) cognitive change and (2) conversion to dementia. Sample
size estimation was carried out for cognitive indexes using the
longpower package in R and LME model was used to estimate
the intercept, slope variances, and residual variances. For the
Table 2 Description of the simple small vessel disease
(SVD) score and the amended score
MRI features
Total SVD score
Simple SVD
score
Amended
score
Microbleeds
≥1 1 1
Lacunes
0 0 0
1–2 1
3–5 1 2
>5 3
White matter hyperintensities
(Fazekas score)
0 0 0
1 1
2 1 2
3 3
Total SVD score (range) 0–3 0–7
Table 3 Study demographic and risk factors at baseline
Demographic and
risk factors
Study, mean (SD) or n (%)
SCANS
(n = 121)
RUN DMC
(n = 503)
ASPS
(n = 1,218)
Age, y 70.0 (9.7) 65.6 (8.8) 65.7 (8.8)
Female 43 (36) 219 (44) 704 (58)
Male 78 (64) 284 (56) 514 (42)
Never smoker 48 (40) 149 (30) 704 (58)
Current smoker 26 (21) 75 (15) 152 (13)
Ex-smoker 47 (39) 279 (55) 351 (29)
Hypertension (no) 9 (7) 134 (27) 448 (37)
Hypertension (yes) 112 (93) 369 (73) 770 (63)
Hypercholesterolemia (no) 18 (15) 266 (53) 229 (19)
Hypercholesterolemia (yes) 103 (85) 237 (47) 989 (81)
Diabetes (yes) 23 (19) 66 (13) 137 (11)
Diabetes (no) 98 (81) 437 (87) 1,081 (89)
Dementia progression (yes) 24 (24)a 65 (31)a 11 (11)a
Dementia progression (no) 97 (97)a 438 (438)a 530 (530)a
Lacunes: none 29 (24) 371 (74) 1,130 (93)
Lacunes: 1 or more 92 (76) 132 (26) 88 (7)
Fazekas score (overall): 0–1 24 (20) 332 (66) 910 (75)
Fazekas score (overall): 2–3 97 (80) 171 (34) 308 (25)
Simple SVD scoreb (n = 541)c
0 12 (10) 261 (52) 366 (68)
1 31 (25) 134 (27) 125 (23)
2 48 (40) 72 (14) 40 (7)
3 30 (25) 36 (7) 10 (2)
Abbreviations: ASPS = Austrian Stroke Prevention Study; RUN DMC = Rad-
boud University Nijmegen Diffusion Imaging and Magnetic Resonance Im-
aging Cohort; SCANS = St George’s Cognition and Neuroimaging in Stroke;
SVD = small vessel disease.
a The number of participants included in the analysis with no missing data
on SVD score. Numbers in parentheses are cases included for vascular de-
mentia analysis.
b Simple SVD score was made without perivascular spaces information with
a range between 0 and 3.
c There were 677 samples with missing cerebral microbleeds information
and the simple SVD score was calculated for 541 samples with completeMRI
information in ASPS.
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binary endpoint of progression to dementia, a Cox regression
model was used with 5 years follow-up. This is the longest
duration follow-up likely to be relevant for a clinical trial. The
powerSurvEpi package in R was used for sample size calculation.
All statistical analyses were carried out in R version 3.3.1.
Data availability
Requests for data from ASPS, SCANS, and RUNDMC should
be made to the individual studies (reinhold.schmidt@medu-
nigraz.at [ASPS], hsm32@medschl.cam.ac.uk[SCANS],
frankerik.deleeuw@radboudumc.nl[RUN DMC]).
Results
Table 3 summarizes the demographics and risk factors of the 3
cohorts. SCANS had participants with the most severe SVD
and ASPS participants with the least severe SVD as reflected
in the proportion of cases with a simple SVD score ≥2: 65% in
SCANS, 21% in RUN DMC, and 9% in ASPS.
Associations with baseline cognition
There were negative associations between the simple SVD score
and baseline cognitive indices. The associations were statistically
significant for the global cognition index and all cognitive do-
main indices except for EF in RUN DMC and ASPS (table e-1,
doi.org/10.17863/CAM.48785). There was a slight improve-
ment in howwell the model fitted (AIC difference >2) when we
used the amended score in SCANS, but the fit was similar in
ASPS and RUN DMC (AIC difference <2).
Prediction of dementia
Adding the simple SVD score to a model including age, sex, and
education years improved prediction as evidenced by an increased
AUC. In an analysis of the pooled datasets, the AUC improved
from 0.76 (95% confidence interval [CI], 0.72–0.80) to 0.81
(95% CI, 0.77–0.85) in a model with the simple SVD score (p =
0.098) and to 0.83 (95% CI, 0.80–0.87) with the amended score
(p = 0.011). When we used vascular dementia cases as the out-
come, the prediction became slightly stronger with AUC = 0.85
Table 4 Assessment of simple and amended small vessel disease (SVD) scores in predicting dementia by study and in
a combined analysis
Study OR (p value) Age, y Sex, M Education, y AUC p Valuea
SCANS (all dementia)
Simple SVD score 1.076 (0.059) 1.01 (0.17) 1.20 (0.02) 0.987 (0.26) 0.71 (0.59–0.82) 0.39
Amended score 1.056 (0.008) 1.01 (0.12) 1.17 (0.04) 0.986 (0.20) 0.74 (0.62–0.86) 0.24
Model without score 1.01 (0.19) 1.19 (0.03) 0.988 (0.28) 0.67 (0.54–0.80) NA
RUN DMC (all dementia)
Simple SVD score 1.02 (0.16) 1.01 (9.3e–13) 1.01 (0.69) 0.997 (0.43) 0.81 (0.77–0.86) 0.55
Amended score 1.02 (0.06) 1.01 (1.7e–12) 1.01 (0.72) 0.997 (0.46) 0.82 (0.77–0.86) 0.47
Model without score 1.01 (2.3e–16) 1.01 (0.67) 0.997 (0.42) 0.81 (0.76–0.86) NA
ASPS (all dementia)
Simple SVD score 1.02 (0.03) 1.001 (0.05) 0.98 (0.15) 0.997 (0.23) 0.83 (0.71–0.96) 0.21
Amended score 1.01 (0.05) 1.001 (0.04) 0.98 (0.16) 0.997 (0.22) 0.84 (0.73–0.95) 0.16
Model without score 1.002 (0.001) 0.997 (0.75) 0.997 (0.07) 0.73 (0.64–0.83) NA
Pooled analysis (all dementia)
Simple SVD score (1) 1.05 (3.2e–07) 1.006 (4.3e–11) 1.03 (0.09) 0.995 (0.04) 0.81 (0.77–0.85) 0.098
Amended score (2) 1.04 (3.2e–13) 1.006 (5.2e–10) 1.02 (0.26) 0.995 (0.06) 0.83 (0.80–0.87) 0.011
Model without score (3) 1.005 (<0.0001) 1.03 (0.003) 0.995 (0.009) 0.76 (0.72–0.80) NA
Pooled analysis (vascular dementia)
Simple SVD score (1) 1.06 (1.2e–14) 1.003 (2.7e–05) 1.02 (0.07) 0.997 (0.17) 0.85 (0.81–0.89) 0.005
Amended score (2) 1.04 (<0.0001) 1.003 (3.4e–05) 1.02 (0.22) 0.997 (0.24) 0.86 (0.82–0.90) 0.002
Model without score (3) 1.003 (8.8e–13) 1.03 (0.003) 0.997 (0.04) 0.76 (0.71–0.81) NA
Abbreviations: ASPS = Austrian Stroke Prevention Study; AUC = area under the curve; OR = odds ratio; RUN DMC = Radboud University Nijmegen Diffusion
Imaging and Magnetic Resonance Imaging Cohort; SCANS = St George’s Cognition and Neuroimaging in Stroke.
a p Value to show significance level of differences among AUC of models (DeLong test for 2 correlated receiver operating characteristic curves), comparing
a model with SVD score and a model without SVD score (both models include age, sex, and education years).
Neurology.org/N Neurology | Volume 94, Number 12 | March 24, 2020 e5
(0.81–89) and 0.86 (0.82–0.90) in a model with the simple score
(p = 0.005) andwith the amended score (p= 0.002), respectively.
Using the amended score appeared to increase the AUC in
SCANS (0.71 vs 0.74) more than RUNDMC (0.81 vs 0.82) and
ASPS (0.83 vs 0.84) (table 4 and figure 1).
A sensitivity analysis, in which the original score10 including
PVS was compared to the simple score without PVS, showed
no significant difference in AUCs (0.69 vs 0.71, p value = 0.35)
and demonstrated that adding PVS did not improve model
prediction (table e-2, doi.org/10.17863/CAM.48785).
We also compared the performance of the score with
a model that also included vascular risk factors (hyperten-
sion, hypercholesterolemia, diabetes mellitus, and smoking)
in addition to age, sex, and education. Including these vas-
cular risk factors slightly improved prediction of dementia
from C = 0.76 to 0.80. The score still resulted in higher
prediction (0.82 for the simple score and 0.84 for the
amended score; amended score vs model without MRI score
p = 0.03) but the additional prediction provided was smaller.
Prediction of cognitive decline
Participants with higher SVD scores showed a greater rate of
decline in global cognition and EF compared to participants
with lower SVD scores in both SCANS and RUN DMC, and
a similar relationship was observed in ASPS. The mean slope
differences among SVD groups were statistically significant in
SCANS and RUN DMC (table e-3, doi.org/10.17863/CAM.
48785 and figure 2). In RUNDMC, there was a similar pattern
for PS, but this relationship was not seen in SCANS and ASPS.
Selection of patients with SVD and its effect on
reduction of sample size for a clinical trial
We determined the effect of selecting patients with a higher
SVD score (≥2) on sample size for a clinical trial assuming
80% power and 5% type 1 error (see Methods). As there
were few cases with high SVD scores in ASPS, this analysis
was limited to data from RUN DMC and SCANS. Results
are shown in table 5. For dementia onset as the outcome
measure, preselection of patients with higher SVD score
reduced sample size by 57% in the pooled dataset. For
cognitive decline as the outcome measure, sample sizes were
reduced by 56%–66% in SCANS and 40%–63% in RUN
DMC depending on which cognitive measure (global cog-
nition, EF, or PS) was the primary endpoint.
Discussion
In this analysis of 3 longitudinal studies covering a range of
SVD severity, we found that a simple SVD score, using meas-
ures readily available by simple review of routine clinical MRI
scans, can aid in predicting which SVD cases will progress to
dementia.
Previous cross-studies3,4 have shown such a score associated
with cognition and we confirmed this in our analysis of the
baseline data. However, whether it can predict dementia can
only be determined by using longitudinal data. By following up
patients over time in longitudinal prospective cohorts, we were
able to demonstrate that the MRI score improved prediction
over that provided by clinical markers such as age, sex, and
Figure 1 Receiver operating characteristic (ROC) curves illustrate the improved prediction of dementia when the simple
MRI score is added to a model adjusted for age, sex, and education
Results are shown for a model
without the MRI score (red line), af-
ter adding a simple MRI score
(green line), and after adding an
amended MRI score (blue line). p
Value shows the statistical differ-
ence among ROC curves (blue:
simple small vessel disease [SVD]
score vs model without score;
green: amended SVD score vs
model without score).
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number of years of education. We also found the score could
predict cognitive decline consistent with a recent report of it
predicting EF in hypertensive individuals.17 Our results are
consistent with a recent longitudinal study showing a similar
MRI summary score predicted dementia in a population-based
Swedish cohort.18
Whereas the results were broadly consistent across pop-
ulations, the score appeared more predictive in studies with
patients with more severe SVD, defined in SCANS as the
presence of confluent WMH. There are several possible
explanations for this. First, the range of MRI scores in ASPS
was low, with only a small number of patients having higher
scores. Second, in cohorts with symptomatic SVD, most cases
of dementia are likely to have a vascular basis and therefore to
be directly related to the SVD. In contrast, in population-
based cohorts such as ASPS, many cases of dementia will be
due to nonvascular causes such as AD, to which SVD will
make a lesser contribution. A clinical implication is that the
MRI score will be most useful in patients who already have
significant SVD, although in view of the association between
WMH and AD it would be interesting to formally test its
predictive value in this population.
To construct the SVD score, a point was given for the pres-
ence or absence of MRI features. However, previous studies
have shown that not only the presence or absence of lacunar
infarcts15 and WMH predicts dementia, but the number of
Figure 2 Cognitive change plotted against simple small vessel disease (SVD) score for the 3 cognitive indices (upper panel,
global cognition; middle panel, executive function; lower panel, processing speed) for the 3 cohorts (St George’s
Cognition and Neuroimaging in Stroke [SCANS], Radboud University Nijmegen Diffusion Imaging and Magnetic
Resonance Imaging Cohort [RUN DMC], and Austrian Stroke Prevention Study [ASPS])
The slopes were used from a linear mixed effect analysis.
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lacunar infarcts and the severity of WMH have additional
predictive value.15,19 Therefore we constructed an amended
score in which there were a number of categories for both the
number of lacunar infarcts and the severity of WMH. This
amended score appeared to improve the predictive ability
slightly. SCANS included patients with more severe SVDwith
a wider range of values; therefore the amended score im-
proved prediction in SCANS slightly more than in the other
cohorts. In contrast, ASPS and RUNDMC, with patients with
milder SVD, had little prediction improvement. We did not
include PVS in the score, as this information was not available
in RUN DMC. However, a sensitivity analysis in those 2
populations with PVS showed no added predictive value,
consistent with a recent meta-analysis showing no association
between PVS and cognition.20
We also examined the hypothesis that SVD score may help
to identify an enriched group of patients and improve the
power of clinical trials. This is of particular importance as
studies including patients with all grades of SVD have failed
to detect cognitive change during follow-up.21 We assessed
this for 2 primary endpoints of cognition and dementia and
showed that selecting patients with severe SVD (as assessed
by simple SVD score) could reduce the sample sizes
moderately.
The strengths of this study are that we determined whether
SVD scores could predict progression to dementia in longi-
tudinal studies. Furthermore, we replicated results across
multiple cohorts and included cohorts with differing severities
of SVD. This allowed us to determine whether the predictive
value differed based on severity of SVD.
The study has limitations. Although these studies were
designed to predict which factor on MRI predicted cognitive
decline, they were not primarily created to answer the cur-
rent clinical question. The analysis involved pooling data
from a number of different populations with different follow-
up periods and methods of assessing dementia incidence.
A simple MRI SVD score based on visual rating can predict
future risk of dementia and cognitive decline.
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